News
![Company](/files/styles/banner/public/bilder/CRO_1_Company_slider_0.jpg?h=d6ca5bbb&itok=5iUiQC-h)
Welcome to the future of translational and early clinical development.
Scientifically driven with access to multiple centres of excellence.
Customisable full service underpinned by the highest quality clinical conduct.
World-leading patient and healthy volunteer recruitment capabilities.
Delivering the best value solution for early clinical development.
Charité Research Organisation GmbH has experience in the conduct of early phase projects for new anti-obesity drugs. We want to share our expertise in this special Whitepaper that comes in three parts.
Many new drug candidates for obesity and related diseases will be discussed according to their development phase in these Whitepapers.
In Part 3, the diverse phenotypes of heart failure (HF) will be discussed with a special focus on the cardiometabolic phenotype of HF with preserved ejection fraction (HFpEF), in which chronic cardiometabolic stress resulting from T2DM and/or obesity are key drivers of HF pathophysiology. The new treatment options for HFpEF with or without obesity will be described including a discussion of the recent class I recommendation for the SGLT2 inhibitors empagliflozin and dapagliflozin [2023 Focused Update of the European Society of Cardiology Guideline in 2021].
Author and Contact:
Claudia Werner, MD, PhD
Charité Research Organisation GmbH
Charitéplatz 1, 10117 Berlin
claudia.werner@charite-research.org
Get in touch with our Business Development Team to find out how Charité Research Organisation can deliver optimal value for your early clinical research projects and help you reach Proof of Concept faster.
Studienberatung
Patienten und Probanden erreichen uns unter (030) 450 539 210.
Please feel free to discuss your early clinical trials with us. Your message will be received attentively by our business development team. We come back to you with feedback from our clinicians and project management experts....
Some more text